Human gene therapy

Critical Reviews in Biotechnology

Volumn 17, Issue 4, 1997, Pages 307-326

  Sandhu, J S ^a,b   Keating, A ^c   Hozumi, N ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

^c Toronto General Hosptial   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GENE THERAPY; GENETIC DISORDER; HUMAN; REVIEW;

GENE THERAPY; GENETIC DISEASES, INBORN; HUMANS;

EID: 0031306774     PISSN: 07388551     EISSN: None     Source Type: Journal    
DOI: 10.3109/07388559709146617     Document Type: Article

References (73)

1. Mulligan RC. The basic science of gene therapy. Science 260(5110): 926-32, 1993.
2. Boris-Lawrie KA and Temin HM. Recent advances in retrovirus vector technology. Curr. Opin. Genet. Dev. 3(1): 102-9, 1993.
3. Wivel NA and Walters L. Germ-line gene modification and disease prevention: some medical and ethical perspectives. Science 262: 533-8, 1993.
4. Morsy MA, Mitani K, Clemens, P, and Caskey, CT. Progress toward human gene therapy. J.Am. Med. Assn. 270: 2338-2345, 1993.
5. Verma IM. Gene therapy. Sci. Am. 263(5): 68-72, 1990.
6. Anderson WF. Human gene therapy. Science 256: 808-813, 1992.
7. Miller AD. Human gene therapy comes of age. Nature 357: 455-460, 1992.
8. Lindahl A, Teumer J, and Green H. Cellular aspects of gene therapy in Westermark B., Gietsholtz C., and Hokfelt G, Eds., Growth Factors in Health and Disease. New York: Elsevier, 1990.
9. Chang JM and Johnson GR. Gene transfer into hematopoietic stem cells using retroviral vectors. Int J Cell Cloning 7: 264-271, 1989.
10. Williams DA. Expression of introduced genetic sequences in hematopoietic cells following retroviral-mediated gene transfer. Hum. Gene Therapy 1: 229-235, 1990.
11. Woiff JA and Lederberg J. A history of gene transfer and therapy. In: Gene Therapeutics Methods and Applications of Direct Gene Transfer. J. A. Wolff, Ed., Boston, Birkhauser, 1994.
12. Evans CH and Robbins PD. Possible orthopaedic applications of gene therapy, J. Bone Jt. Surg. 77(7): 1103-1114, 1995.
13. Anderson WF. Gene therapy for genetic diseases [editorial]. Hum. Gene Ther. 5: 281-282, 1994.
14. Evans CH and Robbins PD. Gene therapy for arthritis. In: Gene Therapeutics. Methods and Applications of Direct Gene Transfer. J. A. Wolff, Ed., Boston, Birkhauser, 1994.
15. Palmer TD, Rosman GJ, Osborne R, and Miller, AD. Genetically modified skin fibroblasts persist long after transplantation but gradually inactivate introduced genes. Proc. Natl. Acad. Sci. U.S.A. 88: 1330-1334, 1991.
16. Correll PH, Colilia S, Dave HP and Karisson S. High levels of human glucocerebrosidase activity in macrophages of long-term reconstituted mice after retroviral infection of hematopoietic stem cells. Blood 80: 331-336, 1992.
17. Crystal RG. Transfer of genes to humans: early lessons and obstacles to success. Science 270: 404-10, 1995.
18. Singhal A and Huang. Gene transfer in mammalian cells using liposomes as carriers. In: Gene Therapeutics. Methods and Applications of Direct Gene Transfer, J. A. Wolff, Ed., Boston, Birkhauser, 1994.
19. Felgner PL, Gadek TR, Ilolm, M, Roman R, Chan HW, Wenz M, Northrop JP, Ringold GM, and Danielsen M. Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proc. Natl. Acad. Sci. U.S.A. 84: 7413-7417, 1987.
20. Nicolau C, Legrand A, and Grosse E. Liposomes as carriers for in vivo gene transfer and expression. Method Enzymol. 149: 157-176, 1987.
21. Rose JK, Buonocore L, and Whitt MA. A new cationic liposome reagent mediating a nearly quantitative transfection of animal cells. BioTechniques 10(4): 520-525, 1991.
22. Nabel GJ, Chang A, Nabel EG, Plants G, Fox BA, Huang L, and Shu S. Clinical protocol: immunotherapy of malignancy by in vivo gene transfer into tumors. Hum. Gene Ther. 3: 399-410, 1992.
23. Wu GY and Wu CH. Receptor-mediated in vitro gene transformation by a soluble DNA carrier system. J. Biol. Chem. 262: 4429-448, 1987.
24. Wu GY, Wilson JM, Shalaby F, Grossman M, Shafritz DA, and Wu CH. Receptor-mediated gene delivery in vivo. Partial correction of genetic analbuminemia in Nagase rats. J. Biol. Chem. 266: 14338-14342, 1991.
25. Perales JC, Ferkol T, Beegen LL, Ratnoff OD, and Hanson RW. Gene transfer in vivo: sustained expression and regulation of genes introduced into the liver by receptor-targeted uptake. Proc. Nat. Acad. Sci. U.S.A. 91: 4086-4090, 1994.
26. Barab D, Hardin J, Sadelain M, and Gage FH. Development of anti-tumor immunity following thymidine kinase-mediated killing of experimental brain tumors. Proc. Natl. Acad. Sci. U.S.A. 91: 4348-4352, 1994.
27. Robbing PD, Tahara H, Mueller G, Flung G, Bahnson A, Zitvogel L, Galea-Lauri J, Ohashi T, Patrene K, Boggs SS, Evans C Ht, Barranger JA, and Lotze MT. Retroviral vectors for use in human gene therapy for cancer, Gaucher disease, and arthritis. Ann. N. Y. Acad. Sci. 716: 72-89, 1994.
28. Cepko CL, Roberts BE, and Mulligan RC. Construction and applications of a highly transmissible murine retrovirus shuttle vector. Cell 7: 1053-1062, 1984.
29. Mulligan RC. Gene transfer and gene therapy: Principles, prospects, and perspective. In: Etiology of Human Disease at the DNA Level. J. Lindsten and U. Pettersson, Eds., New York, Raven Press, 1991.
30. Temin HM. Safety considerations in somatic gene therapy of human disease with retrovirus vectors. Hum. Gene Therapy 1(2): 111-23, 1990.
31. Harel J, Rassart E, and Jolicoer P. Cell cycle dependence of synthesis of unintegrated viral DNA in mouse cells newly infected with murine leukemia virus. Virology 110: 202-210, 1981.
32. Miller DG, Adam MA, Miller AD. Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection. Mol. Cell Biol. 10: 4239-4245, 1990.
33. Rosenfeld MA, Siegfried W, Yoshimura K, Yoncyama K, Fukayama M, Stier LE, Pikkii PK, Gilardi P, Stratford Perricaudet LD, Perricaudet M, Jailat S, Pavirani A, Lecocq J-P, and Crystal RG. Adenovirus-mediated transfer of a recombinant ccl-antitrypsin gene to the lung epithelium in vivo. Science 252: 431-434, 1991.
34. Stratford-Perricaudet LD and Perricaudet M. Gene therapy: the advent of adenovirus. In: Gene Therapeutics. Methods and Applications of Direct Gene Transfer, J. A. Wolff, Ed., Boston, Birkhauser, 1994.
35. Morsy MA, Alford EL, Bett A, Garahm FL, and Caskey AC. Efficient adenoviral-mediated ornithine transcarbamaylase expression in deficient mouse and human hepatocytes. J. Clin. Invest. 92: 1580-1586, 1993.
36. Yang Y, Li Q, Ertl HC, and Wilson JM. Cellular and humoral immune responses to viral antigen carriers to lung-directed gene therapy with recombinant adenoviruses. J. Virol. 69(4): 2004-20015, 1995.
37. Setoguchi Y, Jaffe HA, Chu CS, Crystal RG. Intraperitoneal in vivo gene therapy to deliver alpha 1-antitrypsin to the systemic circulation. Am. J. Respiratory Cell Mol. Biol. 10(4): 369-377, 1994.
38. Smith TA, Mehaffey MG, Kayda DB, Saunders JM, Yei S, Trapnell BC, McClelland A, and Kaleko M. Adenovirus mediated expression of therapeutic plasma levels of human factor IX in mice. Nature Genetics 5(4): 397-402, 1993.
39. Ohno T, Gordon D, San H, Pompili J, Imperiale MJ, Nabel GJ, and Nabel EG. Gene therapy for vascular smooth muscle cell proliferation after arterial injury. Science 265: 781-784, 1994.
40. Kotin RM. Prospects for the use of adeno-associated virus as a vector for human gene therapy. Hum. Gene Ther. 5: 793-801, 1994.
41. Samulski RJ, Zhu X, Xiao X, Brook JD, Housman DE, Epstein N, and Hunter LA. Targeted integration of adenoassociated virus (AAV) into human chromosome 19. EMBO J. 10: 3941-3950, 1991.
42. Kaplitt MG, Leone P, Samulski RJ, Xiao X, Pfaff DW, O'Malley KL, and During MJ. Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain. Nature Genet. 8: 148-154, 1994.
43. Glorioso JC, DeLuea NA, Goins WE, and Fink DJ. In: Gene Therapeutics. Methods and Applications of Direct Gene Transfer, J. A. Wolff, Ed., Boston, Birkhauser, 1994.
44. Sandhu JS, Boynton E, and Hozumi N. The use of SCID mice in biotechnology and as a human disease model. Crit. Rev. Biotechnol. 16: 95-118, 1996.
45. Rooney, CM, Smith CA, Ng CY, Brenner MK, Heslop HE, Loftin S, Li C, and Krance RA. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 345: 9-13, 1995.
46. Brenner MK, Rill DR, Holladay MS, Heslop HE, Moen RC, Buschle M, Krance RA, Santana VM, and Anderson WF. Gene marking to determine whether autologous marrow infusion restores long-term haemopoiesis in cancer patients. Lancet 342: 1134-1137, 1993.
47. Cornetta K, Srour EF, Moore A, Davidson A, Broun ER, Hromas R, Moen RC, Morgan RA, Rubin L, Anderson WF, Hoffman R, and Tricot G. Retroviral gene transfer in autologous bone marrow transplantation for adult acute leukemia. Hum. Gene Therapy 7(11): 1323-1329, 1996.
48. Cai Q, Rubin JT, and Lotze MT. Genetically marking human cells - resulls of the first clinical gene transfer studies. Cancer Gene Therapy 2(2): 125-136, 1995.
49. Lu DR, Zhou JM, Zheng B, Qiu QF, Xue JL. et al. Stage I clinical trial of gene therapy for hemophilia B. Science in China-series B. Chemistry, Life Sciences and Earth Sciences 36(11): 1342-1351, 1993.
50. Kredich NM and Hershfield MS. The Metabolic Basis of Inherited Disease, McGraw-Hill, New York, 1989.
51. Blaese RM, Culver KW, Miller AD et al. T lymphocyte-directed gene therapy for ADA-SCID: initial trial results after 4 years. Science 270: 475-480, 1995.
52. Kohn DB, Weinberg KI, Nolta JA, Heiss LN, Lenarsky C, Crooks GM, Hanley ME, Annett G, Brooks JS, El-Khoureiy A et al. Engraftment of gene-modified umbilical cord blood cells in neonates with adenosine deaminase deficiency. Nature Med. 1(10): 1017-1023, 1995.
53. Hanley ME, Nolta JA, Parkman R, and Kohn DB. Umbilical cord blood cell transduction by retroviral vectors: preclinical studies to optimize gene transfer. Blood Cells 20: 539-543, 1995.
54. Bordignon C, Notarangelo LG, Nobili, N. et al. Gene therapy in peripheral blood lymphocytes in bone marrow for ADA-immunodeficient patients. Science 270: 470-474, 1995.
55. Brown MS, Goldstein JL, Havel RJ, and Steinberg D. Gene therapy. Nature Genetics 7(3): 349-350, 1994.
56. Grossman M, Raper SE, Kozarsky K, Stein EA, Engelhardt JF, Muller D, Lupien PJ, and Wilson JM. Successful ex vivo gene therapy directed to liver in a patient with familial hypercholesterolaemia. Nature Genetics 6(4): 335-341, 1994.
57. Riordan JR, Rommens JM, Kerem B, Alon N, Rozmahel R, Grzelczak Z, Zielenski J, IS, Plavsic N, Chou JL et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 245(4922): 1066-73, 1989.
58. Rosenfeld MA, Voshimura K, Trapnell BC, Yoneyama K, Rosenthal ER, Dalemans W, Fukayama M, Bargon J, Stier LE, Stratford-Perricaudet L, Perricaudet M, Guggino WB, Pavirani A, Lecocq J-P, and Crystal RG. In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium. Cell 68: 143-155. 1992.
59. Wilson JM. Cystic fibrosis: strategies for gene therapy. Semin. Resp. Crit. Care Med. 15: 439-445, 1994.
60. Knowles MR, Hohneker KW, Zhou Z, Olsen JC, Noah TL, Hu PC, Leigh MW, Engelhardt JF, Edwards LJ, Jones KR. et al. A controlled study of adenoviral vector-mediated gene transfer in the nasal epithelium of patients with cystic fibrosis. N. Engl. J. Med. 333(13): 823-831, 1995.
61. Ginns E, Choudan PV, Martin BM, Winfield S, Stubblefield B, Mayor J, Merkle-Lehman D, Murray GJ, Bowers LA, and Barranger JA. Isolation of cDNA clones for human beta-glucocerebrosidase using the lambda expression system. Biochem. Biophys. Res. Commun. 123: 574-58, 1984.
62. Tsuji S, Choudar PV, Martin BM, Winfield S, Barranger JA, and Ginns E. Nucleotide sequence of cDNA containing the complete coding sequence for human lysosomal glucocerebrosidase. J.Biol. Chem. 261: 50-53, 1986.
63. Choudary PV, Barranger JA, Tsuji S, Mayor J, LaMarca ME, Cepko CL, Mulligan RC, and Ginns EI. Retrovirus-mediated transfer of the human glucocerebrosidase gene to Gaucher fibroblasts. Mol. Biol. Med. 3: 293-299, 1986.
64. Sorge J, Kuhl W, West C, and Beutler E. Complete correction of the enzymatic defect of type I Gaucher disease fibroblasts by retroviral-mediated gene transfer. Proc. Natl. Acad. Sci. U.S.A. 84: 906-909, 1987.
65. Correll PH, Colilia S, Dave HP, and Karisson S. High levels of human glucocerebrosidase activity in macrophages of long-term reconstituted mice after retroviral infection of hematopoietic stem cells. Blood 50: 331-336, 1992.
66. Ohashi T, Boggs S, Robbing P, Bahnson A, Patrene K, Wei FS, Wei JF, Li J, Lucht L, Fei Y, Clark S, Kimak M, He H, Mowery-Rushton P, and Barranger JA. Efficient transfer and sustained high expression of the human glucocerebrosidase gene in mice and their functional macrophages following transplantation of bone marrow transduced by a retroviral vector. Proc. Natl. Acad. Sci. U.S.A. 89: 11332-11336 1992.
67. + cells with the glucocerebrosidase cDNA. Gene Ther. 1: 201-207, 1994.
68. Kohn D. Retroviral-mediated transfer of the cDNA for human glucocerebrosidase into hematopoietic stem cells of patients with Gaucher disease. A phase I study. Human Gene Therapy 7(2): 231-53, 1996.
69. Elder EM, Lotze MT, and Whiteside TL. Successful culture and selection of cytokine gene-modified human dermal fibroblasts for the biologic therapy of patients with cancer. Human Gene Therapy 7(4): 479-87, 1994.
70. Brenner MK. et al. Recombinant DNA Advisory Commitee 9206-92018.
71. Nabel GJ, Nabel EG, Yang ZY, Fox BA, Plautz GE, Gas X, Huang L, Shu S, Gordon D, and Chang AE. Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans. Proc. Natl. Acad. of Sci. U.S.A. 90(23): 11307-11311, 1993.
72. Nabel EG, Yang Z, Muller D, Chang AE, Gas X, Huang L, Cho KJ, and Nabel GJ. Safety and toxicity of catheter gene delivery to the pulmonary vasculature in a patient with metastatic melanoma. Human Gene Therapy 5(9): 1089-1094, 1994.
73. Ram ZG and Oldfield EH. Toxicity studies of retroviral-mediated gene transfer for the treatment of brain tumors. J. Neurosurgery 79(3): 400-407, 1993.